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Beta-adrenergic blocking agents known as 
beta blockers are widely used in clinical prac-
tice to treat several cardiovascular disorders 
such as hypertension and high blood pressure 
in general. They are also used as cardiopro-
tective agents in post myocardial infarction, 
for  the  treatment  of  cardiac  arrhythmias 
and were reported to be beneficial in treat-
ing migraine. Recently, they were shown to 
be efficacious in treating patients with several 
types of congenital long QT syndromes and 
in patient with catecholaminergic polymor-
phic ventricular tachycardia.
They  mainly  act  by  antagonizing  the 
effects  of  norepinephrine  released  from 
sympathetic nerve endings on beta adren-
oceptors.  A  direct  interaction  with  ion 
channels in addition to the beta blocking 
property is now becoming more and more 
accepted  in  the  scientific  community. 
Propranolol is the beta blocker prototype, 
it is commonly used as racemic mixture 
with equal concentrations of R-(+)- and 
S-(−)-enantiomers.  Although,  they  have 
been classified as class II antiarrhythmic 
drugs by Vaughan Williams the molecular 
mechanisms by which they act is not fully 
elucidated. On the other hand, their ben-
eficial effect in preventing migraine is not 
well understood.
Earlier electrophysiological studies have 
reported the effects of propranolol on heart 
rate  and  conduction  properties  in  frog 
auricular fibers, rat, and canine ventricu-
lar myocytes. Recent data have shown that 
beta blockers could modulate Nav1.5, the 
cardiac voltage-gated sodium channels, but 
the effect on the expressed brain sodium 
channels was not envisaged. In the paper by 
Wang et al., the authors studied the effect 
of propanol on heterologously expressed 
recombinant human cardiac (Nav1.5) and 
the three brain (Nav1.1, Nav1.2, and Nav1.3) 
sodium  channels  using  whole-cell  patch 
clamp recordings.
Previous work from the author’s group 
showed  that  racemic  propranolol  and 
R-(+)-propranolol block Nav1.5 channels 
(Wang et al., 2008). In this paper the authors 
extended their study to evaluate the molec-
ular mechanism of the reported block. Both 
R-(+) and S-(−) propranolol block Nav1.5 
sodium channels in tonic and phasic (use-
dependent or frequency-dependent) man-
ner with similar affinities. However, nadolol 
a non-selective beta blocker and metopro-
lol a selective beta 1 blocker did not induce 
any tonic or phasic block, suggesting that 
the sodium   channel block property is not 
common to all beta blockers. More detailed 
biophysical  studies  from  the  authors 
revealed  that  that  R-(+)-propranolol 
exhibits biophysical effects on Nav1.5 that 
are similar but not identical to lidocaine, 
the class 1 antiarrhythmic drug prototype. 
That R-(+)-propranolol acts as a typical 
local anesthetic and class 1 antiarrhyth-
mics on sodium channels by interacting 
with specific residues in the DIV-S6 seg-
ment, including the phenylalanine-1760, 
known to play a central role in drug binding 
(Ragsdale et al., 1994) and therefore shares 
this property with established antiarrhyth-
mic  drugs.  Finally,  further  detailed  bio-
physical study from the authors showed 
that the brain sodium channels (Nav1.1, 
Nav1.2, and Nav1.3) exhibit less sensitiv-
ity to R-(+)-propranolol than the Nav1.5 
channels. Since the phenylalanine-1760 is 
a conserved residue in all sodium channels, 
including brain sodium channels, studies to 
elucidate the basis of this reduced affinity 
at molecular level are warranted.
These data reported by Wang et al., in 
this issue of Frontiers in Pharmacology of 
Ion  Channel  and  Channelopathies,  will 
pave the path toward a more understand-
ing of the effect of beta blockers on sodium 
  channels, a widely used class of drugs.
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